Loading…
Sichuan-based pharmaceutical manufacturer selling drugs in China.
Sichuan-based pharmaceutical manufacturer selling drugs in China.
Moat: none
Headquarters: Sichuan, China · Employees: 1,366
Size Sichuan Huiyu Pharmaceutical (688553.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.07B, the 2169th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥11.43 on 6 Nov 2026.
Performance Over six months the shares fell 15.3%, against -15.7% for the median peer and -16.4% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 8.0% over the last twelve months (peer median +8.3%); the operating margin is 6.6% (peer median 8.7%).
Valuation It trades at 4.7× enterprise value to sales against a peer median of 3.2× (5th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 34% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is +40 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.9 points below its cost of capital (9.1% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.10B | CN¥996M | CN¥1.09B | CN¥924M | CN¥1.49B |
| Revenue growth | — | -9% | +18% | -38% | — |
| Gross profit | CN¥797M | CN¥737M | CN¥849M | CN¥759M | CN¥1.28B |
| EBITDA | CN¥170M | CN¥110M | CN¥143M | CN¥69.9M | CN¥185M |
| Net income | CN¥113M | -CN¥25.0M | CN¥325M | CN¥140M | CN¥249M |
| Free cash flow | CN¥179M | CN¥26.4M | CN¥135M | -CN¥194M | -CN¥220M |
| Capital expenditure | CN¥76.9M | CN¥105M | CN¥128M | CN¥297M | CN¥462M |
| Total debt | CN¥777M | CN¥648M | CN¥594M | CN¥436M | CN¥55.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688553.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.0% | -7.5% | 6th highest of 21 |
| 6-month return | -15.3% | -15.7% | 11th highest of 21 |
| Distance from 52-week high | -34.0% | -35.5% | 10th highest of 21 |
| Revenue growth (TTM) | +8.0% | +8.3% | 10th lowest of 20 |
| Operating margin | 6.6% | 8.7% | 9th lowest of 20 |
| EV / Sales | 4.7× | 3.2× | 5th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 34.1% | 4.2% | 3rd most demanding of 13 |
| Growth delivered (Del g) | -6.0% | +5.7% | 3rd lowest of 13 |
| Hurdle (Req g minus delivered) | +40.2 pp | +1.4 pp | most demanding of 13 |
| ROIC minus cost of capital | -5.9 pp | -0.2 pp | 5th lowest of 18 |
| EV / EBITDA | 30.3× | 12.3× | 2nd most expensive of 6 |
| Net debt / EBITDA | -11.8× | 0.4× | least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $1.07B | -15% | +8% | 7% | 4.7× | 34.1% | -6.0% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.07B | -38% | +117% | -89% | 14.8× | n/a | n/a |
| Viyash Scientific VIYASH.NS | India | $1.07B | +3% | +96% | 13% | 3.2× | 38.6% | +20.4% |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.07B | +27% | +5% | 24% | 3.2× | -5.7% | +12.7% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.08B | -2% | +27% | 4% | 2.4× | 5.0% | +3.5% |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $1.07B | -47% | -55% | -457% | 68.9× | n/a | n/a |
| BeBetter Med 688759.SS | China | $1.08B | -49% | n/a | n/a | n/a | n/a | n/a |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $1.06B | -18% | -27% | -19% | 3.0× | n/a | n/a |
| Renhe Pharmacy 000650.SZ | China | $1.06B | -10% | -7% | 14% | 1.0× | -9.4% | -7.0% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.09B | -35% | -2% | 13% | 4.5× | 5.5% | +7.7% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $1.09B | -15% | -4% | 2% | 1.4× | n/a | n/a |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $1.05B | -6% | +8% | 7% | 1.5× | 3.4% | +1.8% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.10B | -29% | +103% | 24% | 4.3× | 8.6% | -4.5% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $1.10B | -51% | +19% | 9% | 4.3× | 13.9% | +4.9% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -13% | +31% | -7% | 1.8× | -6.4% | -7.7% |
| Bio-Thera Solutions 688177.SS | China | $1.10B | -14% | +24% | -44% | 7.6× | n/a | n/a |
| Blue Jet Healthcare BLUEJET.NS | India | $1.11B | +13% | -28% | 28% | 11.8× | 49.0% | +13.8% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.11B | -13% | -7% | 3% | 1.6× | 3.3% | +6.5% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -16% | +7% | 9% | 1.2× | 1.5% | +12.1% |
| SAWAI 4887.T | Japan | $1.03B | -22% | +11% | 9% | 1.3× | n/a | n/a |
| ST Pharm 237690.KS | South Korea | $1.12B | -52% | +26% | 18% | 3.8× | n/a | n/a |